GlassScriptPhysician profile
Isabela T Jones
NPI 1790041853
$6,568.32
in general payments reported to CMS, 2019-2025
30 companies · $1,807 in 2025
The $1,807 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $470 · 2020: $114 · 2021: $92.12 · 2022: $1,030 · 2023: $1,416 · 2024: $1,639 · 2025: $1,807.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,862.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,862.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $1,101.61 | 2022-2025 | |
| Abbvie INC. | $726.85 | 2019-2025 | Rinvoq, Skyrizi |
| Merz North America, INC. | $646.88 | 2019-2025 | Xeomin |
| Incyte Corporation | $596.64 | 2021-2025 | Opzelura |
| Janssen Biotech, INC. | $534.93 | 2022-2025 | Tremfya |
| Pfizer INC. | $403.29 | 2019-2025 | |
| Galderma Laboratories, L.P. | $361.07 | 2019-2025 | Aklief, Nemluvio, Oracea |
| Arcutis Biotherapeutics, INC. | $339.19 | 2023-2025 | Zoryve |
| Regeneron Healthcare Solutions, INC. | $303.15 | 2022-2025 | Dupixent |
| Sun Pharmaceutical Industries INC. | $219.72 | 2021-2025 | Absorica Ld, Winlevi |
| Amgen INC. | $203.39 | 2022-2025 | Otezla, Otezla, Enbrel |
| Mayne Pharma Commercial LLC | $193.33 | 2019 | |
| Lilly USA, LLC | $158.24 | 2022-2024 | Olumiant, Taltz, Ebglyss |
| E.R. Squibb & Sons, L.L.C. | $137.99 | 2023-2024 | Sotyktu |
| Novartis Pharmaceuticals Corporation | $86.04 | 2019-2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almirall LLC | $82.69 | 2019-2020 | |
| Ucb, INC. | $81.31 | 2025 | Bimzelx |
| Dermavant Sciences, INC. | $55.94 | 2022-2024 | Vtama |
| Leo Pharma INC. | $55.36 | 2019-2025 | Adbry |
| Journey Medical Corporation | $44.87 | 2022-2025 | |
| Vyne Pharmaceuticals INC. | $32.39 | 2020-2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $31.80 | 2019-2020 | |
| Glenmark Therapeutics INC. | $30.00 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.65 | 2023 | Spevigo |
| Aclaris Therapeutics, INC. | $24.83 | 2019 | |
| Medimetriks Pharmaceuticals, INC. | $24.17 | 2025 | |
| Mission Pharmacal Company | $18.05 | 2022 | |
| Mylan Pharmaceuticals INC. | $16.80 | 2019 | |
| Solta Medical, A Division of Bausch Health US, LLC | $15.96 | 2024 | Clear+Brilliant |
| Epi Health, LLC | $13.18 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Isabela Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.